Login / Signup

Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.

Henri-Jean AubinIvan BerlinJulien GuiraudJacques BruhwylerPhilippe BatelPascal PerneyBenoît TrojakPatrick BendimeradMorgane Guillou-LandreatMichaël BischMarie Grall-BronnecDamien LabarrièreDominique DelsartFrank QuestelRomain MoirandPhilippe BernardFabrice TroveroHang Phuong PhamJean-Pol TassinAlain Puech
Published in: Addiction (Abingdon, England) (2024)
A randomized controlled trial of treatment of severe alcohol use disorder with a cyproheptadine-prazosin combination for 3 months reduced drinking by more than 23 g per day compared with placebo. A higher dose combination was associated with a larger magnitude of drinking reduction than a lower dose combination while showing similar safety profile.
Keyphrases
  • alcohol use disorder
  • double blind
  • clinical trial
  • study protocol
  • combination therapy
  • phase iii
  • smoking cessation
  • drug induced